Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2024-2032
세계의 자궁경부암 진단 시장 규모는 2023년 80억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 123억 달러에 이를 전망이고, 예측 기간 동안 4.8%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
자궁경부암 진단은 인유두종 바이러스(HPV)의 비정상적인 세포와 균주를 평가하기위한 일련의 고급 임상 검사, 도구 및 절차에 의존합니다. 이러한 검사는 콘 절제술, 펀치 생검, 자궁 경부 내 긁힘, 콜포스카피 중 자궁 경부의 정밀 검사를 위한 전선 루프에 의해 얻은 조직 샘플을 채취하여 수행됩니다. 발견 후는 혈액 검사, 흉부 X선 검사, CT 검사, MRI 검사, PET 검사, 방광이나 직장의 시촉진 등을 실시하여 병기를 판정합니다.
매독, 클라미디아, 임질, 후천성 면역 결핍 증후군(HIV/AIDS) 등 성행위 감염증(STI)으로 진단되는 환자 수가 대폭 증가하고 있기 때문에 세계의적으로 HPV 감염의 위험이 높아지고 있습니다. 이것은 자궁경부암의 발병 가능성을 높이는 흡연자 증가와 함께 시장 성장을 뒷받침하는 주요 요인 중 하나입니다. 또한 조기 진단에 대한 의식이 높아짐에 따라 신속하고 정확한 검사 결과를 제공하는 HPV 가정용 검사 키트의 채택을 뒷받침하고 있습니다. 유리한 상환 정책의 존재도 시장 성장을 지원합니다. 이와는 별도로, 맞춤 치료계획에 대한 기호의 고조가 자궁경부암 진단 수요를 높이고 있습니다. 또한 수술, 방사선 요법, 화학 요법, 옥수수 생검, 면역 요법, 기관 절제술 등 다양한 치료 옵션을 사용할 수 있다는 점도 시장 성장에 기여합니다. 게다가 저비용으로 효율적인 검사 제품의 개발이 중시되고 있는 것도 시장의 성장을 뒷받침할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 자궁경부암 진단 시장 시장 규모는?
- 2024-2032년에 있어서의 자궁경부암 진단 시장 시장 성장률은?
- 세계의 자궁경부암 진단 시장을 견인하는 주요 원인은 무엇인가?
- 세계의 자궁경부암 진단 시장에 대한 COVID-19의 영향은?
- 세계의 자궁경부암 진단 시장의 검사 유형별 내역은?
- 자궁경부암 진단 시장의 주요 지역은?
- 세계의 자궁경부암 진단 시장에서 주요 진출기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 자궁경부암 진단 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 검사 유형별
- 팝 검사
- HPV 검사
- 자궁 경부 생검
- 질경 검사
- 기타
제7장 시장 분석 : 연령층별
제8장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Arbor Vita Corporation
- Becton, Dickinson and Company
- Cooper Surgical Inc.
- F. Hoffmann-La Roche AG
- Guided Therapeutics Inc.
- Hologic Inc.
- Qiagen
- Quest Diagnostics Incorporated
- Siemens Healthcare GmbH
BJH
The global cervical cancer diagnostics market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.
Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.
A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cervical cancer diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and age group.
Breakup by Test Type:
Pap Testing
HPV Testing
Cervical Biopsies
Colposcopy
Others
Breakup by Age Group:
20 to 35 years
Above 35 years
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.
Key Questions Answered in This Report
- 1. How big is the global cervical cancer diagnostics market?
- 2. What is the expected growth rate of the global cervical cancer diagnostics market during 2024-2032?
- 3. What are the key factors driving the global cervical cancer diagnostics market?
- 4. What has been the impact of COVID-19 on the global cervical cancer diagnostics market?
- 5. What is the breakup of the global cervical cancer diagnostics market based on the test type?
- 6. What are the key regions in the global cervical cancer diagnostics market?
- 7. Who are the key players/companies in the global cervical cancer diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cervical Cancer Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Test Type
- 6.1 Pap Testing
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 HPV Testing
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Cervical Biopsies
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Colposcopy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Age Group
- 7.1 20 to 35 years
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Above 35 years
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Arbor Vita Corporation
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Becton, Dickinson and Company
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Cooper Surgical Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 F. Hoffmann-La Roche AG
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 Guided Therapeutics Inc.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 SWOT Analysis
- 13.3.7 Hologic Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Qiagen
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Quest Diagnostics Incorporated
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Siemens Healthcare GmbH
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 SWOT Analysis
